Clinical Trial

Effect of Intrauterine Administration of Autologous PBMC Modulated With IFNt on IVF Outcome

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 21, 2025 (before its estimated March 13, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to test the effect of modulated specialised immune cells isolated from the patients' own blood when administered to the uterus before embryo transfer on the IVF outcome (implantation, pregnancy and live birth rates). To achieve this, blood will be obtained from eligible participants. Target cells will be isolated and incubated with the tested modulator for 24h, and returned to the uterine cavity 1 day prior to embryo transfer. Researchers will compare the reproductive outcome of the tested intervention to that of a control group who will not receive the investigated cell treatment prior to embryo transfer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-03-07; most recent amendment 2025-05-20.
Trial Details
NCT Number NCT05775198
Lead Sponsor Nadezhda Women's Health Hospital
Conditions Infertility, Female, IVF
Enrollment 300 participants
Start Date 2023-03-01
Primary Completion 2026-03-13 (estimated)
Study Completion 2026-04-28 (estimated)
Updated on ClinicalTrials.gov 2025-05-21